3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
221
Polycystic Ovary Syndrome
36
Endometrial Neoplasms
15
Ovarian Neoplasms
13
Infertility
11
Neoplasm Metastasis
9
Carcinoma, Intraductal, Noninfiltrating
7
Fallopian Tube Neoplasms
6
Neoplasms
5
Breast Diseases
5
Triple Negative Breast Neoplasms
4
Osteoporosis
4
Leiomyoma
4
Infertility, Female
4
Breast Neoplasms, Male
4
Breast Carcinoma In Situ
4
Arthralgia
4
Advanced Breast Cancer
4
Recurrence
3
Obesity
3
Breast Cancer Metastatic
3
Anovulation
3
Uterine Neoplasms
2
Solid Tumor
2
Prostatic Neoplasms
2
Progesterone Resistance
2
Pancreatic Neoplasms
2
Pain
2
Leiomyosarcoma
2
HR Positive HER2 Negative Advanced Breast Cancer
2
Interventions
Carboplatin
5
pembrolizumab
4
Trastuzumab
4
Oxaliplatin
4
Fluorouracil
4
Cyclophosphamide
4
Radiotherapy
3
Paclitaxel
3
Endoscopy
3
Docetaxel
3
Cytarabine
3
Chemoradiotherapy
3
Capecitabine
3
toripalimab
2
Tretinoin
2
Surgical Procedures, Operative
2
Standard of Care
2
Observation
2
Neoadjuvant Therapy
2
Metformin
2
Magnetic Resonance Imaging
2
Leucovorin
2
Irinotecan
2
Immunotherapy
2
Immune Checkpoint Inhibitors
2
Epirubicin
2
Drug Therapy
2
Doxorubicin
2
Cisplatin
2
Blood Specimen Collection
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Pathologic Complete Response
×
Letrozole
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled